| ○種別 (必須): | □ | 学術論文 (審査論文)
| [継承] |
| ○言語 (必須): | □ | 英語
| [継承] |
| ○招待 (推奨): |
| ○審査 (推奨): |
| ○カテゴリ (推奨): |
| ○共著種別 (推奨): |
| ○学究種別 (推奨): |
| ○組織 (推奨): |
| ○著者 (必須): | 1. | 友成 哲
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 2. | 佐藤 康史 ([徳島大学.大学院医歯薬学研究部.医学域.連携研究部門(医学域).寄附講座系(医学域).地域消化器・総合内科学])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 3. | 田中 宏典 ([徳島大学.病院.先端医科医療開発研究プロジェクト]/[徳島大学.病院.診療科.内科.消化器内科])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 4. | 田中 貴大
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): | □ | ****
| [ユーザ] |
| [継承] |
| 5. | 谷口 達哉
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): | □ | ****
| [ユーザ] |
| [継承] |
| 6. | 曽我部 正弘 ([徳島大学.キャンパスライフ健康支援センター])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 7. | 岡本 耕一 ([徳島大学.病院.診療科.内科.消化器内科])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 8. | 宮本 弘志 ([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.内科系.消化器内科学]/[徳島大学.病院.診療科.内科.消化器内科])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 9. | 六車 直樹
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 10. | 齋藤 裕 ([徳島大学.病院.診療科.外科.消化器・移植外科])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 11. | 居村 暁
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 12. | 坂東 良美 ([徳島大学.病院.診療科.病理診断科])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 13. | 島田 光生 ([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.外科系.消化器・移植外科学])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 14. | 高山 哲治 ([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.内科系.消化器内科学])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| ○題名 (必須): | □ | (英) Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib Three case reports. (日)
| [継承] |
| ○副題 (任意): |
| ○要約 (任意): | □ | (英) Lenvatinib (LEN) is a novel potent multi-tyrosine kinase inhibitor, approved as first-line treatment for unresectable hepatocellular carcinoma (HCC). Considering its high objective response rate, LEN therapy could be expected to achieve downstaging of tumors and lead to conversion therapy with hepatectomy or ablation. However, the feasibility of conversion therapy after LEN treatment in unresectable HCC remains largely unknown. Here, we reported 3 cases of unresectable HCC: case 1, a 69-year-old man diagnosed with ruptured HCC; case 2, a 72-year-old woman with nonalcoholic steatohepatitis-based HCC; and case 3, a 73-year-old man with a history of alcoholic cirrhosis-based HCC. In all cases, cirrhosis was classified as Child-Pugh 5 and modified albumin-bilirubin grade 1 or 2a. HCC was diagnosed as Barcelona Clinic Liver Cancer (BCLC) stage B. In all cases, LEN was initiated after conventional-transcatheter arterial embolization enforcement, while maintaining liver function. In all cases, the main tumor size decreased after 6 months of LEN treatment and no satellite nodes were detected, indicating downstaging of HCC to BCLC stage A. Subsequently, conversion hepatectomy or ablation was performed. After successful conversion therapy, the general condition of the patients was good, without tumor recurrence during the observation period (median 10 months). This study demonstrated that LEN enables downstaging of HCC and thus represents a bridge to successful surgery or ablation therapy. In particular, LEN treatment may facilitate the possibility for conversion therapy of initially unresectable HCC, while maintaining the hepatic functional reserve. (日)
| [継承] |
| ○キーワード (推奨): | 1. | (英) Ablation Techniques (日) (読)
| [継承] |
| 2. | (英) Aged (日) (読)
| [継承] |
| 3. | (英) Biomarkers (日) (読)
| [継承] |
| 4. | (英) Carcinoma, Hepatocellular (日) (読)
| [継承] |
| 5. | (英) Female (日) (読)
| [継承] |
| 6. | (英) Hepatectomy (日) (読)
| [継承] |
| 7. | (英) Humans (日) (読)
| [継承] |
| 8. | (英) Liver Neoplasms (日) (読)
| [継承] |
| 9. | (英) Male (日) (読)
| [継承] |
| 10. | (英) Phenylurea Compounds (日) (読)
| [継承] |
| 11. | (英) Protein Kinase Inhibitors (日) (読)
| [継承] |
| 12. | (英) Quinolines (日) (読)
| [継承] |
| 13. | (英) alpha-Fetoproteins (日) (読)
| [継承] |
| ○発行所 (推奨): |
| ○誌名 (必須): | □ | Medicine ([Lippincott Williams & Wilkins])
(pISSN: 0025-7974, eISSN: 1536-5964)
| ○ISSN (任意): | □ | 0025-7974
ISSN: 0025-7974
(pISSN: 0025-7974, eISSN: 1536-5964) Title: MedicineTitle(ISO): Medicine (Baltimore)Publisher: Lippincott Williams and Wilkins Ltd. (NLM Catalog)
(Scopus)
(CrossRef)
(Scopus information is found. [need login]) | [継承] |
| [継承] |
| ○巻 (必須): | □ | 99
| [継承] |
| ○号 (必須): | □ | 42
| [継承] |
| ○頁 (必須): | □ | e22782 e22782
| [継承] |
| ○都市 (任意): |
| ○年月日 (必須): | □ | 西暦 2020年 9月 18日 (令和 2年 9月 18日)
| [継承] |
| ○URL (任意): |
| ○DOI (任意): | □ | 10.1097/MD.0000000000022782 (→Scopusで検索)
| [継承] |
| ○PMID (任意): | □ | 33080748 (→Scopusで検索)
| [継承] |
| ○CRID (任意): |
| ○WOS (任意): |
| ○Scopus (任意): |
| ○評価値 (任意): |
| ○被引用数 (任意): |
| ○指導教員 (推奨): |
| ○備考 (任意): | 1. | (英) Article.ELocationID: 10.1097/MD.0000000000022782 (日)
| [継承] |
| 2. | (英) Article.PublicationTypeList.PublicationType: Case Reports (日)
| [継承] |
| 3. | (英) Article.PublicationTypeList.PublicationType: Journal Article (日)
| [継承] |